Table 2 The subgroups analysis for VEGF and overall survival in patients with osteosarcoma
Subgroup | Number of studies | Model | Heterogeneity test | Effect size | Conclusion | |||
|---|---|---|---|---|---|---|---|---|
I2 | p value | HR | 95%CI | p value | ||||
Ethnicity | ||||||||
Asian | 8 | Fixed | 0.0% | 0.774 | 2.49 | 1.85–3.35 |  < 0.001 | Significant |
Non-Asian | 3 | Fixed | 0.0% | 0.695 | 2.20 | 1.34–3.61 | 0.002 | Significant |
Publication (year) | ||||||||
 ≥ 2014 | 5 | Fixed | 0.0% | 0.833 | 1.94 | 1.32–2.83 | 0.001 | Significant |
 < 2014 | 6 | Fixed | 0.0% | 0.942 | 2.87 | 2.04–4.04 |  < 0.001 | Significant |
Testing isoform | ||||||||
IHC | 10 | Fixed | 0.0% | 0.959 | 2.45 | 1.84–3.25 |  < 0.001 | Significant |
qRT-PCR | 1 | – | – | – | – | – | – | – |
Antibody type | ||||||||
Santa Cruz | 5 | Fixed | 0.0% | 0.896 | 2.65 | 1.83–3.83 | 0.001 | Significant |
Others | 4 | Fixed | 0.0% | 0.795 | 2.18 | 1.40–3.40 |  < 0.001 | Significant |
Positivity (%) | ||||||||
 ≥ 55% | 7 | Fixed | 0.0% | 0.731 | 1.98 | 1.31–2.99 | 0.001 | Significant |
 < 55% | 4 | Fixed | 0.0% | 0/892 | 2.71 | 1.96–2.75 |  < 0.001 | Significant |
HR resource | ||||||||
Reported | 5 | Fixed | 0.0% | 0.868 | 2.20 | 1.87–3.11 |  < 0.001 | Significant |
SC | 6 | Fixed | 0.0% | 0.894 | 2.73 | 1.85–4.02 |  < 0.001 | Significant |
Sample size | ||||||||
 ≥ 50 | 7 | Fixed | 0.0% | 0.915 | 2.19 | 1.63–2.94 |  < 0.001 | Significant |
 < 50 | 4 | Fixed | 0.0% | 0.722 | 3.20 | 1.92–5.34 |  < 0.001 | Significant |
NOS score | ||||||||
 < 8 | 6 | Fixed | 0.0% | 0.800 | 2.495 | 1.72–3.62 |  < 0.001 | Significant |
 ≥ 8 | 5 | Fixed | 0.0% | 0.663 | 2.335 | 1.65–3.31 |  < 0.001 | Significant |